Details

Autor(en) / Beteiligte

• Vella, Laura A
• Giles, Josephine R
• Baxter, Amy E
• Oldridge, Derek A
• Diorio, Caroline
• Kuri-Cervantes, Leticia
• Alanio, Cécile
• Pampena, M Betina
• Wu, Jennifer E
• Chen, Zeyu
• Huang, Yinghui Jane
• Anderson, Elizabeth M
• Gouma, Sigrid
• McNerney, Kevin O
• Chase, Julie
• Burudpakdee, Chakkapong
• Lee, Jessica H
• Apostolidis, Sokratis A
• Huang, Alexander C
• Mathew, Divij
• Kuthuru, Oliva
• Goodwin, Eileen C
• Weirick, Madison E
• Bolton, Marcus J
• Arevalo, Claudia P
• Ramos, Andre
• Jasen, C J
• Conrey, Peyton E
• Sayed, Samir
• Giannini, Heather M
• D'Andrea, Kurt
• Meyer, Nuala J
• Behrens, Edward M
• Bassiri, Hamid
• Hensley, Scott E
• Henrickson, Sarah E
• Teachey, David T
• Betts, Michael R
• Wherry, E John

Titel

Deep immune profiling of MIS-C demonstrates marked but transient immune activation compared to adult and pediatric COVID-19

Ist Teil von

• Science immunology, 2021-03, Vol.6 (57)

Ort / Verlag

United States

Erscheinungsjahr

2021

Quelle

MEDLINE

Beschreibungen/Notizen

• Pediatric COVID-19 following SARS-CoV-2 infection is associated with fewer hospitalizations and often milder disease than in adults. A subset of children, however, present with Multisystem Inflammatory Syndrome in Children (MIS-C) that can lead to vascular complications and shock, but rarely death. The immune features of MIS-C compared to pediatric COVID-19 or adult disease remain poorly understood. We analyzed peripheral blood immune responses in hospitalized SARS-CoV-2 infected pediatric patients (pediatric COVID-19) and patients with MIS-C. MIS-C patients had patterns of T cell-biased lymphopenia and T cell activation similar to severely ill adults, and all patients with MIS-C had SARS-CoV-2 spike-specific antibodies at admission. A distinct feature of MIS-C patients was robust activation of vascular patrolling CX3CR1+ CD8+ T cells that correlated with the use of vasoactive medication. Finally, whereas pediatric COVID-19 patients with acute respiratory distress syndrome (ARDS) had sustained immune activation, MIS-C patients displayed clinical improvement over time, concomitant with decreasing immune activation. Thus, non-MIS-C versus MIS-C SARS-CoV-2 associated illnesses are characterized by divergent immune signatures that are temporally distinct from one another and implicate CD8+ T cells in the clinical presentation and trajectory of MIS-C.